Interaction between the serotonergic, dopaminergic, and glutamatergic systems in fenfluramine-induced Fos expression in striatal neurons
- 1 January 1998
- Vol. 28 (1) , 71-82
- https://doi.org/10.1002/(sici)1098-2396(199801)28:1<71::aid-syn9>3.0.co;2-9
Abstract
Fenfluramine (FE) is a halogenated amphetamine derivative used in the treatment of obesity and thought to induce serotonin (5-HT) release from nerve terminals and to reduce re-uptake. However, other pathways may also be involved. In this work, the effects of FE on the major striatal afferent systems, and the possible interactions of these systems in FE-induced striatal expression of Fos, were studied by lesion of the serotonergic and/or dopaminergic system and administration of NMDA glutamate (MK-801) or D1 dopamine (SCH-23390) receptor antagonists. Both the D1 and NMDA receptor antagonists suppressed Fos expression in response to FE almost entirely. FE-induced Fos expression was also dramatically reduced 24 h after 6-hydroxydopamine (6-OHDA) lesion of the dopaminergic system. However, the reduction was not so marked after chronic 6-OHDA lesion, probably due to compensatory changes. Chronic (5,7-dihydroxytryptamine injection, 4 weeks before) or acute (p-chlorophenylalanine injection) lesion of the serotonergic system led to a marked reduction in Fos expression in response to FE (decrease of about 50%). After simultaneous chronic lesion of both serotonergic and dopaminergic systems, a considerable number of Fos-positive nuclei were still observed (decrease of about 70% in the dorsal and dorsomedial regions). The FE-induced expression of Fos was almost totally suppressed (decrease of about 95% in the dorsal and dorsomedial regions) after simultaneous acute lesion. Our results indicate that FE-induced striatal expression of Fos is due in large measure to DA release and dopaminergic stimulation of D1 receptors. However, concurrent stimulation of NMDA glutamate receptors also appears to be essential, and 5-HT release (although not indispensable) doubles striatal Fos expression. Synapse 28:71–82, 1998.Keywords
This publication has 50 references indexed in Scilit:
- Basal ganglia and movement disorders: an updateTrends in Neurosciences, 1996
- Serotonin Enhances Striatal Dopamine Outflow In Vivo Through Dopamine Uptake SitesJournal of Neurochemistry, 1996
- d‐Fenfluramine Increases Striatal Extracellular Dopamine In Vivo Independently of Serotonergic Terminals or Dopamine Uptake SitesJournal of Neurochemistry, 1995
- Evidence for 5-HT4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized ratNeuropharmacology, 1995
- Transection of Corticostriatal Afferents Reduces Amphetamine‐ and Apomorphine‐induced Striatal Fos Expression and Turning Behaviour in Unilaterally 6‐Hydroxydopamine‐lesioned RatsEuropean Journal of Neuroscience, 1993
- Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatumJournal of Neurophysiology, 1992
- Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatumNeuroscience, 1992
- The functional anatomy of basal ganglia disordersTrends in Neurosciences, 1989
- The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptorsEuropean Journal of Pharmacology, 1986
- 5-Hydroxytryptamine and 5-hydroxytryptaminergic-dopaminergic interactions in the ventral tegmental area of rat brainJournal of Pharmacy and Pharmacology, 1982